164 related articles for article (PubMed ID: 25623760)
1. [Effect of recombinant human p53 adenovirus (Ad-p53) combined with EGFR inhibitor gefitinib on the sensitivity of breast cancer MDA-MB-468 cells].
Wang X; Guan X; Wang L; Xie L; Liu Q; Yu Z
Zhonghua Zhong Liu Za Zhi; 2014 Dec; 36(12):886-91. PubMed ID: 25623760
[TBL] [Abstract][Full Text] [Related]
2. Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.
Wang X; Song H; Yu Q; Liu Q; Wang L; Liu Z; Yu Z
Oncol Rep; 2015 Feb; 33(2):526-32. PubMed ID: 25501339
[TBL] [Abstract][Full Text] [Related]
3. [Effect of autophagy inhibitor combined with EGFR inhibitor on triple-negative breast cancer MDA-MB-468 and MDA-MB-231 cells].
Liu ZY; He KW; Song XG; Wang XZ; Zhuo PY; Wang XW; Ma QH; Huo ZJ; Yu ZY
Zhonghua Zhong Liu Za Zhi; 2016 Jun; 38(6):417-24. PubMed ID: 27346398
[TBL] [Abstract][Full Text] [Related]
4. Tumor-suppressive effect of adenovirus-mediated inhibitor of growth 4 gene transfer in breast carcinoma cells in vitro and in vivo.
Li Z; Xie Y; Sheng W; Miao J; Xiang J; Yang J
Cancer Biother Radiopharm; 2010 Aug; 25(4):427-37. PubMed ID: 20707719
[TBL] [Abstract][Full Text] [Related]
5. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
Normanno N; De Luca A; Maiello MR; Campiglio M; Napolitano M; Mancino M; Carotenuto A; Viglietto G; Menard S
J Cell Physiol; 2006 May; 207(2):420-7. PubMed ID: 16419029
[TBL] [Abstract][Full Text] [Related]
6. Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT-mTOR pathway.
Deng M; Wang J; Chen Y; Zhang L; Liu D
Anticancer Drugs; 2015 Apr; 26(4):422-7. PubMed ID: 25588160
[TBL] [Abstract][Full Text] [Related]
7. Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231).
Takabatake D; Fujita T; Shien T; Kawasaki K; Taira N; Yoshitomi S; Takahashi H; Ishibe Y; Ogasawara Y; Doihara H
Int J Cancer; 2007 Jan; 120(1):181-8. PubMed ID: 17036319
[TBL] [Abstract][Full Text] [Related]
8. AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib.
Maiello MR; D'Alessio A; De Luca A; Carotenuto A; Rachiglio AM; Napolitano M; Cito L; Guzzo A; Normanno N
Breast Cancer Res Treat; 2007 May; 102(3):275-82. PubMed ID: 17004112
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous inhibition of EGFR and PI3K enhances radiosensitivity in human breast cancer.
Li P; Zhang Q; Torossian A; Li ZB; Xu WC; Lu B; Fu S
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e391-7. PubMed ID: 22414288
[TBL] [Abstract][Full Text] [Related]
10. Combinatorial treatment of non-small-cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy.
Emdad L; Lebedeva IV; Su ZZ; Gupta P; Sarkar D; Settleman J; Fisher PB
J Cell Physiol; 2007 Feb; 210(2):549-59. PubMed ID: 17111370
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib induces apoptosis and decreases telomerase activity in MDA-MB-231 human breast cancer cells.
Moon DO; Kim MO; Heo MS; Lee JD; Choi YH; Kim GY
Arch Pharm Res; 2009 Oct; 32(10):1351-60. PubMed ID: 19898796
[TBL] [Abstract][Full Text] [Related]
12. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
13. miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1.
Zhou G; Zhang F; Guo Y; Huang J; Xie Y; Yue S; Chen M; Jiang H; Li M
Biomed Pharmacother; 2017 Jan; 85():113-119. PubMed ID: 27930974
[TBL] [Abstract][Full Text] [Related]
14. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of everolimus in combination with paclitaxel on adriamycin-resistant breast cancer cell line MDA-MB-231.
Xu T; Liu P; Li Q; Shi C; Wang X
Taiwan J Obstet Gynecol; 2020 Nov; 59(6):828-834. PubMed ID: 33218396
[TBL] [Abstract][Full Text] [Related]
16. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
17. [Effect of Fuzheng Kang'ai Recipe Combined Gefitinib on Lung Cancer A549 Cells and Its Mecha- nism Research].
Yang XB; Chen X; Wu WY; Long SQ; Chen SM; Han SW
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2016 Nov; 36(11):1340-1344. PubMed ID: 30641628
[TBL] [Abstract][Full Text] [Related]
18. Caspase-dependent and caspase-independent induction of apoptosis in breast cancer by fucoidan via the PI3K/AKT/GSK3β pathway in vivo and in vitro.
Xue M; Ji X; Xue C; Liang H; Ge Y; He X; Zhang L; Bian K; Zhang L
Biomed Pharmacother; 2017 Oct; 94():898-908. PubMed ID: 28810530
[TBL] [Abstract][Full Text] [Related]
19. [Effect of gefitinib on the migration of triple-negative breast cancer cell line MDA-MB-231 cells].
Zhao HM; Zhang B; Li Y; Zhang L; Zhang F; Song YQ; Feng WH; Cao WF; Cao XC
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):84-8. PubMed ID: 22780923
[TBL] [Abstract][Full Text] [Related]
20. EGFR inhibitor C225 Increases the Radio-Sensitivity of Human Breast Cancer Cells.
Yao Z; Peng P; Xu D; Zhou X; Pan Z; Li Z; Yao J; Chen J
Asian Pac J Cancer Prev; 2019 Jan; 20(1):311-319. PubMed ID: 30678455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
